Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo. Under the terms of the agreement, Syndax received an upfront payment of $350M in exchange for a 13.8% royalty on U.S. net sales of Niktimvo. Royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.35x.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
- Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
- Royalty Pharma price target lowered to $40 from $60 at Citi
- Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug
- PureTech Health announces FDA approval of KarXT